Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

W. Stöhr, T. Langer, A. Kremers, I. Brecht, J. Treuner, A. Dinnesen, J. D. Beck*

*Corresponding author for this work
12 Citations (Scopus)

Abstract

The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m2, the remaining with 500 mg/m2. We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

Original languageEnglish
JournalOncology Reports
Volume12
Issue number4
Pages (from-to)767-771
Number of pages5
ISSN1021-335X
DOIs
Publication statusPublished - 10.2004

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Dive into the research topics of 'Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System'. Together they form a unique fingerprint.

Cite this